Laurus Labs Limited Q1 FY27 Earnings Call Summary

Event Participants

Executives

4 Krishna Chaitanya Chava, Satyanarayana Chava, Soumya Chava, Vantaram Venkata Ravi Kumar

Analysts

12 Bharat Sheth, Dhawal Khut, Krish Mehta, Manoj Bahety, Mitul Mehta, Nitin Agarwal, Rehan Saiyyed, Sachin Jain, Sajal Kapoor, Tushar Manudhane, Vandit Dharamshi, Unknown Analyst

Financials & KPIs

Geographic & Segment Commentary

CDMO - Small Molecule: Q1 FY27 revenue of ₹835 crores, up 69% YoY, driven by acceleration in late-stage clinical and commercial deliveries for multiple global partners. Commercial supplies contributed 55% of CDMO revenue (vs 50% in FY26); the balance is largely Phase III supply programs expected to convert to commercial. Portfolio is well-diversified across products, customers, and therapeutic areas with no significant concentration; all CDMO programs are innovator/on-patent molecules.

Laurus Bio: Q1 FY27 revenue of ₹35 crores, up 21% YoY, supported by customer revenue diversification and pipeline progress on larger global accounts in animal-origin-free and CDMO segments. Revenue mix: ~20% from animal-origin-free cell culture ingredients and enzymes; balance from early-stage CDMO molecules spanning alternative food proteins, colors, and super absorbent polymers. Phase I commercial fermentation capacity (400+ kiloliters) expected operational by end-CY2026; upstream/downstream capacity is fungible across programs.

Affordable Medicines (Generics): Q1 FY27 revenue of ₹1,156 crores, up 10% YoY, driven by higher volumes across established ARV and oncology portfolios where market leadership is maintained. Non-ARV now constitutes ~2/3 of division revenue; management expects ARV share to decline further. Accelerating product registrations across 3 emerging markets; new South Africa office established to capture regional growth. Cumulative DMF filings at 92; 2 formulation dossiers filed in Q1 (cumulative 96).

Company-Specific & Strategic Commentary

• ADC & Next-Generation Modalities: Signed development and commercial agreement with Aarvik Therapeutics for 2 ADC molecules (MUTTA program, solid tumors) for India, with a small strategic equity stake held. Licensed 2 preclinical assets with in-vitro proof-of-concept complete; GLP toxicity expected to start mid-CY2027, with India revenue potential in 3-4 years. Also licensed IIT Kanpur patents for gene therapy and invested in ImmunoACT for lentiviral/cell therapy capabilities.

• Peptides: Investing in commercial-scale peptide capacity at Vizag based on customer demand; programs span multiple classes beyond GLP-1. Management expects peptides to be a meaningful growth area but declined project-specific details.

• Krka JV: Oncology small-volume formulation facility ready early CY2027; large-volume solid oral facility in H2 CY2027. ₹400 crores invested to date with ~₹400 crores additional required, partly funded through partner loan.

• Capacity & Infrastructure: Final handover of 500+ acres land parcel from AP government in final stages. Q1 CapEx of ₹394 crores directed toward purpose-built capacity for near-term partner needs.

• Commercial Expansion: New South Africa office established; registrations accelerated across 3 emerging markets to build a more diversified growth pipeline.

• ESG & Quality: 24 regulatory/customer quality audits passed without critical findings; SBTi validated near-term science-based emission reduction targets.

• Capital Allocation: Strategy prioritizes high-value business segments; up to 10% of profits allocated to disruptive technologies (in-house or external). Management expects current seeding of new areas to drive growth from FY30 onward.

Guidance & Outlook

Risks & Constraints

Q&A Highlights

CapEx Guidance Escalation & Drivers

• Question: What changed to nearly double CapEx guidance from ₹1,000 crores to ₹2,000 crores within 6-8 months? (Vandit Dharamshi; similar by Bharat Sheth)
• Answer: The increase reflects capacity required to meet customer demands; investments are purpose-built for near-term partner needs across multiple customers, products, and programs — not for one customer. The incremental ₹500 crores covers multiple products spanning both Human Health and Animal Health, predominantly API (with some advanced intermediates). FY27-28 combined CapEx may exceed the earlier ₹3,000-crores guidance, but no precise number is available. (Satyanarayana Chava)

CDMO Commercial Mix & Run-Rate Sustainability

• Question: Is late-stage delivery revenue sustainable? What is the commercial vs non-commercial split? (Tushar Manudhane)
• Answer: 55% of small-molecule CDMO revenue came from commercial supplies in Q1 FY27 vs 50% in FY26; the remainder is largely Phase III supplies expected to become commercial — one program has already obtained regulatory approval, and the offtake is a global portfolio spanning regulated and LMIC markets. (Satyanarayana Chava, Krishna Chaitanya Chava)
• Question: Can the current custom-synthesis run rate be maintained at roughly ±₹100 crores? (Dhawal Khut)
• Answer: Yes, that is a fair statement. (Krishna Chaitanya Chava)

ARV Split & Portfolio Mix Stabilization

• Question: Can you disclose the ARV API/FDF split, and is the 1/3-2/3 ARV/non-ARV mix now stable? (Krish Mehta)
• Answer: ARV API was ₹415 crores and ARV FDF ₹254 crores, totaling ₹669 crores. Non-ARV is now 2/3 of the Affordable Medicines portfolio; management expects ARV share to decline further, not rise. (Soumya Chava, Satyanarayana Chava)

Conviction Through the FY23 Downturn

• Question: What gave you conviction to keep investing during the weak FY23 period when stock and results were under pressure? (Sajal Kapoor)
• Answer: CDMO customers want capacity visible before awarding programs and avoid site changes to minimize regulatory complexity. Management invested aggressively — taking risk but not bankruptcy risk — and that capacity attracted complex, scaled projects. FY23's large purchase order execution was the precedent; without prior capacity, Laurus would have missed the CDMO opportunity. (Satyanarayana Chava)
• Answer: The CFO added that 7 weaker quarters were navigated with balanced judgment ("read Bhagavad Gita well"), and those investments have been paying off for the last 5 quarters. (Vantaram Venkata Ravi Kumar)

Capital Allocation Across Three Horizons

• Question: How do you balance harvesting, scaling, and seeding investments across time horizons? (Sajal Kapoor)
• Answer: Long-gestation bets (gene therapy, ADC, cell therapy) are conscious investments in modalities growing faster than the core; small-molecule API and drug-product CapEx is predictable given better visibility. Up to 10% of profits are allocated to disruptive technologies, in-house or external. Major new-area investments take 4-5 years; current seeding targets growth from FY30 onward. (Satyanarayana Chava, Vantaram Venkata Ravi Kumar)

Aarvik Therapeutics ADC Deal & Future Modalities

• Question: What is the structure of the Aarvik partnership and what products are involved? (Unknown Attendee)
• Answer: Laurus made a small strategic investment in Aarvik and licensed 2 preclinical ADC assets (MUTTA program) targeting solid tumors, with in-vitro proof-of-concept complete. GLP toxicity is expected to start mid-CY2027 in India, with revenue 3-4 years away. Separately, the company licensed IIT Kanpur patents for gene therapy, invested in ImmunoACT for lentiviral/cell therapy, and is building large-scale peptide capacity — positioning for where the market is moving. (Satyanarayana Chava, Krishna Chaitanya Chava)

Krka JV Status

• Question: How much more CapEx is required for the Krka JV and when will revenues begin? (Manoj Bahety)
• Answer: The oncology small-volume facility will be ready early next year (CY2027) and the large-volume solid oral facility in H2 CY2027. ₹400 crores invested to date; another ~₹400 crores is required, partly funded through a loan from the partner. (Satyanarayana Chava)

ROCE & Asset Turnover Trajectory

• Question: With cumulative CapEx now crossing ₹4,700 crores, what is the expected trajectory for asset turnover and ROCE? (Rehan Saiyyed)
• Answer: Asset turnover will exceed 1.0x for sure — the company is "almost there right now." Reaching 25% ROCE will take time due to heavy CapEx, but ROCE is already improving: 17.7% in FY26 to ~19% in Q1 FY27, and should continue to grow. (Satyanarayana Chava)

Laurus Bio Outlook & Product Mix

• Question: How predictable is the fermentation and precision-fermentation business including Vizag 400+ kL capacity? (Sajal Kapoor)
• Answer: The current ~₹200 crores (Bio + Crop Sciences combined) is confident; the next ramp-up depends on multiple products. The next 12-18 months will be crucial in determining which precision-fermentation programs scale. Upstream/downstream capacity is fungible, so lessons from failed programs can be redeployed to new molecules. (Satyanarayana Chava)
• Question: Which product categories are largest within Laurus Bio? (Dhawal Khut)
• Answer: ~20% from animal-origin-free cell culture ingredients and enzymes; the remaining ~60% from early-stage CDMO molecules spread across alternative food proteins, colors, and super absorbent polymers — no single concentrated segment. (Satyanarayana Chava)

CDMO Diversification & FY30 Target

• Question: Is CDMO growth concentrated in 2-3 products? What could a blockbuster contribution look like? (Mitul Mehta, Unknown Analyst)
• Answer: CDMO revenue is well-diversified across products, customers, and therapeutic areas; no single program or customer has high concentration. All CDMO programs are innovator/on-patent molecules; some programs already generate ₹200+ crores annually. Program value matters more than program count — a blockbuster for the customer doesn't necessarily translate to a large API opportunity given dosage and value-per-milligram differences. (Krishna Chaitanya Chava)
• Question: Will the CDMO >50% revenue target be achieved earlier than FY30? (Unknown Analyst)
• Answer: Management is comfortable that at least 50% of revenue will come from CDMO by FY30. (Satyanarayana Chava)

Key Takeaway

Laurus Labs delivered record Q1 FY27 results — revenue of ₹2,026 crores (+29% YoY), EBITDA of ₹644 crores (31.8% margin, +7pp QoQ), and PAT of ₹368 crores — led by 69% CDMO growth to ₹835 crores and 10% Affordable Medicines growth to ₹1,156 crores. FY27 CapEx guidance was raised to ~₹2,000 crores for partner-driven capacity across multiple products, with FY27-28 combined spend potentially exceeding ₹3,000 crores. Strategic investments span peptides, ADCs (Aarvik Therapeutics in-licensing), gene therapy, and the Krka JV; Laurus Bio's 400+ kL fermentation Phase I is on track for end-CY2026. Management reaffirmed ≥50% CDMO revenue share by FY30 and >1.0x asset turnover, while cautioning that 25% ROCE will take time under heavy CapEx. Watch points: CDMO Phase III-to-commercial conversions, Bio ramp-up over the next 12-18 months, and margin resilience amid global supply-chain conflicts.